Race Oncology Limited announced that Mr. Damian Clarke-Bruce has been appointed Managing Director and Chief Executive Officer, effective 1 February 2023. Mr. Phil Lynch will return to his prior role as a Non-Executive Director of Race Oncology and will work closely with Mr. Clarke-Bruce to ensure a smooth and effective leadership transition. Dr Tillett will continue in his leadership role as Chief Scientific Officer and Executive Director.

Mr. Clarke-Bruce brings deep global experience in drug commercialisation and portfolio strategy. He has held executive roles at all stages of the drug development process, from pre-clinical evaluation through to successful commercial launch. He has identified an defined new markets for pharma assets and has overseen product registration, access and reimbursement, medical marketing, and commercial sale.

He brings an extensive network from within the pharmaceutical industry, as well as exceptional relationships with key opinion leaders across several therapeutic areas, including oncology, haematology and immunology. Mr. Clarke-Bruce was most recently the Executive Director of Marketing Global/US Commercial Lead in Rare Disease and Head of the Global Launch Leadership Team for Pharming Healthcare Inc, New Jersey.